Immunoglobulin G1, anti-(human interleukin-17A), human monoclonal AIN457 γ1 heavy chain (230-215')-disulfide with human monoclonal AIN457 κ light chain dimer (236-236'':239-239'')-bisdisulfide;Secukinumab
Cas No.
1229022-83-6
包装储存
Please store the product under the recommended conditions in the Certificate of Analysis.
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
性状
Liquid
IC50 & Target[1][2]
IL-17A
体外研究(In Vitro)
Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A.Secukinumab (1 nM, 10 nM, and 100 nM) inhibits IL17A and IL17A/TNF a-induced increase in protein levels of IL6 in human astrocytes. has not independently confirmed the accuracy of these methods. They are for reference only.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145.[2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315.[3]. Elain G, et al